E-LIB Suche - Ergebnisse für: You, Shuhui

1

Real-world data of triplet combination of pyrotinib, trastu..:

You, Shuhui ; Sang, Die ; Xu, Fei...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10748899/. , 2023

Link: http://www.ncbi.nlm.nih...

2

Clinicopathological characteristics, evolution, treatment p..:

You, Shuhui ; Gong, Chengcheng ; Li, Yi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595148/. , 2023

Link: http://www.ncbi.nlm.nih...

3

Comparing pyrotinib with trastuzumab and pertuzumab with tr..:

You, Shuhui ; Xie, Yizhao ; Sang, Die...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10750407/. , 2023

Link: http://www.ncbi.nlm.nih...

4

Pretreatment (18)F‐FDG uptake heterogeneity may predict tre..:

Ma, Guang ; You, Shuhui ; Xie, Yizhao...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510219/. , 2023

Link: http://www.ncbi.nlm.nih...

5

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy..:

Xie, Yizhao ; Du, Xinyue ; Zhao, Yannan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323202/. , 2022

Link: http://www.ncbi.nlm.nih...

6

Development and validation of nomograms to intraoperatively..:

Zhao, Fei ; Lu, Rong-Xin ; Liu, Jin-Yuan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786479/. , 2021

Link: http://www.ncbi.nlm.nih...

7

Clinicopathological characteristics, evolution, treatment p..:

Shuhui You ; Chengcheng Gong ; Yi Li...
https://www.frontiersin.org/articles/10.3389/fendo.2023.1270453/full. , 2023

Link: https://doi.org/10.3389/..

8

ER status conversion and subsequent treatment: an assessmen..:

Shuhui You ; Yizhao Xie ; Mengjing Ji...
https://doi.org/10.1177/17588359231216093. , 2023

Link: https://doi.org/10.1177/..

9

Comparing pyrotinib with trastuzumab and pertuzumab with tr..:

Shuhui You ; Yizhao Xie ; Die Sang...
https://www.frontiersin.org/articles/10.3389/fendo.2023.1325540/full. , 2023

Link: https://doi.org/10.3389/..

10

Pretreatment 18F‐FDG uptake heterogeneity may predict treat..:

Guang Ma ; Shuhui You ; Yizhao Xie...
https://doi.org/10.1186/s40644-023-00608-0. , 2023

Link: https://doi.org/10.1186/..

11

Image_1_Comparing pyrotinib with trastuzumab and pertuzumab..:

Shuhui You ; Yizhao Xie ; Die Sang...
doi:10.3389/fendo.2023.1325540.s001. , 2023

Link: https://doi.org/10.3389/..

12

Table_1_Comparing pyrotinib with trastuzumab and pertuzumab..:

Shuhui You ; Yizhao Xie ; Die Sang...
doi:10.3389/fendo.2023.1325540.s002. , 2023

Link: https://doi.org/10.3389/..

13

Image_1_Clinicopathological characteristics, evolution, tre..:

Shuhui You ; Chengcheng Gong ; Yi Li...
doi:10.3389/fendo.2023.1270453.s001. , 2023

Link: https://doi.org/10.3389/..

14

sj-docx-1-tam-10.1177_17588359231217972 – Supplemental mate..:

Shuhui You ; Die Sang ; Fei Xu...
doi:10.25384/sage.24901218.v1. , 2023

Link: https://doi.org/10.25384..

15

Image_1_Comparing pyrotinib with trastuzumab and pertuzumab..:

Shuhui You ; Yizhao Xie ; Die Sang...
doi:10.3389/fendo.2023.1325540.s001. , 2023

Link: https://doi.org/10.3389/..